Linked Color Imaging (LCI) for Colorectal Adenoma Detection
Launched by VALDUCE HOSPITAL · Sep 27, 2018
Trial Information
Current as of May 18, 2025
Completed
Keywords
ClinConnect Summary
50-75 years-old subjects participating in the regional screening program undergoing their first colonoscopy following a positive immunochemical fecal occult blood test (FIT) and meeting all eligibility criteria are randomised 1:1 to LCI (LCI group) or WLI (WL) during insertion and withdrawal phase of colonoscopy. A randomisation list for each participating center was produced by the coordinating center via computer-generated treatment code list. Randomisation is stratified by gender, age (50-60, 61-729 years) and screening history (first vs subsequent test) through an online centralised stu...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 50-75 years-old subjects participating in the regional screening program undergoing their first colonoscopy following a positive immunochemical fecal occult blood test (FIT)
- Exclusion Criteria:
- • subjects not eligible for invitation in the screening program (colonoscopy already performed in the previous 5 years, personal history of CRC, colonic adenomas or IBD, severe comorbidity, including end-stage cardiovascular, pulmonary, liver or renal disease)
- • patients with inadequate bowel preparation (defined as Boston Bowel Preparation Scale \> 2 in any colonic segment)
- • patients with previous colonic resection
- • patients on antithrombotic therapy, precluding polyp resection
- • patients who were not able or refused to give informed written consent.
About Valduce Hospital
Valduce Hospital is a leading healthcare institution dedicated to advancing medical research and improving patient outcomes through innovative clinical trials. With a commitment to excellence in patient care and safety, Valduce Hospital collaborates with experienced researchers and healthcare professionals to conduct rigorous studies across various therapeutic areas. By leveraging state-of-the-art facilities and cutting-edge technologies, Valduce Hospital strives to contribute to the development of new treatments and therapies, ensuring that patients have access to the latest advancements in medicine. The hospital’s dedication to ethical standards and regulatory compliance positions it as a trusted partner in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Como, , Italy
Patients applied
Trial Officials
Franco Radaelli, MD
Principal Investigator
Valduce Hospital, Como
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials